Gene Editing Market Report By Technology (CRISPR, TALEN, ZFN, Antisense, and others), By Application (Genetic Engineering, Gene Therapy, Cell Line Engineering, and Others), By End User (Biotechnology and Pharmaceutical Companies, Contract Research Organizations and Academic & Government Research Institutes) and by Regions, 2023-2032

Report Overview

The global gene editing market size was valued at USD 7.2 billion in 2022 and is expected to grow at a CAGR of 18.1% from 2023 to 2032. It is expected to reach USD 36.4 billion by 2032. The field of gene editing involves the introduction or substitution of material DNA.

Gene editing refers to the process of modifying the DNA sequence of an organism. This is accomplished using types of enzymes, like CRISPR/Cas9, TALENs or ZFNs which have the ability to make changes in the makeup. The applications of editing are diverse and impactful ranging from treating inherited diseases to improving crop quality. Additionally, it provides insights into understanding the mechanisms behind these diseases. As a result, the adoption of editing is rapidly increasing not in life sciences but also in fields like medicine and agriculture. It is anticipated that genome editing will play a role, in shaping the industry in the years to come.

Recent advancements, in gene editing technologies have greatly improved the speed, simplicity and accuracy of modifying DNA cells. These technologies are now being applied in areas such as research, medicine, agriculture, biotechnology and pest control. Gene editing shows promising potential for treating diseases, infectious diseases and cancer. The growth of the gene editing market is further driven by increasing collaborations between public entities and advancements, like Clustered Interspaced Short Palindromic Repeats (CRISPR).

Furthermore, the growth in Research & Development (R&D) activities focused on gene editing is contributing to the increasing revenue in the market. As an example scientist at the University of Marylands College of Agriculture and Natural Resources have developed a technique called CRISPR Combo. This innovative approach allows for the editing of genes in plants while also modifying the expression of genes. The development of this technology with support from the National Institute of Food and Agriculture under the United States Department of Agriculture (USDA) will facilitate genetic engineering combinations that work together to enhance functionality and improve breeding methods, for crops.

The markets expansion is being driven by government regulations concerning biology a growing demand, for engineered genes and cells and increased investments from both the government and large corporations. Another noteworthy development in gene therapy and molecular biology that has contributed to the markets growth is the introduction and utilization of gene editing methods for editing purposes.

Furthermore, the availability of user gene therapy systems, advancements, in engineering and the potential of gene therapy to enable rapid genome wide analyses of gene function are all factors influencing gene editing market growth during the forecast period.

Driving Factors

The Increasing Production of Genetically Modified Crops Is Predicted to Boost the Genome Editing Market's Growth Pace

The use of editing techniques is becoming more popular in the development of modified crops. Currently gene editing is employed to improve the yield of crops enhance their ability to resist pests and diseases and make them adaptable to conditions. The demand for modified crops is increasing worldwide due to the growing population and the need for food production. Consequently, gene editing is playing a role in the development of genetically modified crops leading to gene editing market growth.

Increasing numbers of strategic initiatives

Various companies and research institutions are actively pursuing initiatives such as mergers, acquisitions and partnerships to gain an advantage in the field of gene editing. For example, in April 2022 Thermo Fisher Scientific launched the Gibco CTS TrueCut Cas9 Protein specifically designed for editing.

Moreover, Intellia Therapeutics and Regeneron Pharmaceuticals reported promising results in February 2022 for their leading candidate NTLA 2001, an in genome editing treatment targeting Transthyretin Amyloidosis. GenScript Biotech Corporation has also introduced a CRISPR Gene Editing Cell Line Engineering Service that enables editing for both research and therapeutic purposes. These advancements demonstrate a dedication, to advancing genomic editing technologies.

Rising Demand for Synthetic Genes in Emerging Markets Will Propel Industry Expansion

The increasing need, for genes in developing countries is predicted to fuel the growth of the gene editing market during the study period. In emerging economies synthetic genes are particularly well suited for enhancing modified (GM) crops. By modifying plant metabolic pathways synthetic genes can improve efficiency and nutritional quality.

When it comes to developing and modifying crops researchers tend to favour the CRISPR/Cas9 technology. However, this method requires government approvals for manufacturing modified crops. Furthermore, there is a growing demand for genes, in medicine development to combat cancer, which is expected to boost the gene editing market share in the years ahead.

Restraining Factors

Hindering The Expansion of the Genome Editing Market Is Ethical Concerns Around Crop Genomic Editing

One of the important factor that hampers the growth of the market is the presence of limitations. Issues, like hurdles genome editing technology, lack of awareness in certain countries and the availability of alternative technologies are expected to have a negative impact, on the expansion of the genome editing market. Furthermore, concerns regarding animal welfare can arise at stages of generation while the lifespan of modified animals poses challenges to the gene editing market.

Expensive Cost of Gene-related equipment Is Impeding the Gene Editing Market

Gene instruments comes with functionalities and features which is why their price falls in the premium range of 10 to 20 million USD. Since pharmaceutical companies and research institutions often require systems, the overall cost of acquiring these genomic instruments becomes quite high. However smaller pharmaceutical companies and research facilities might find it challenging to invest amounts, in genomic instruments due to financial constraints. Similarly, academic research labs face budget limitations that make it difficult for them to finance systems. Nevertheless, technical advancements are paving the way, for the development of devices. Consequently, the high equipment costs may not pose a long term obstacle to the growth of the Gene Editing market.

By Technology Type

CRISPR/Cas9 sector is the dominating player in the gene editing market capturing the share of revenue at 43.7%. It is expected to continue dominating the market during the forecast period. One of the reasons for its dominance is the ability to target sites simultaneously within a cell using different guide RNAs. The ease of use and higher efficiency compared to technologies make CRISPR a popular choice, among researchers and companies involved in cell line engineering, animal engineering and plant genetic engineering.

The widespread acceptance of CRISPR is evident in the increasing number of trials focused on addressing conditions like AIDS, cancer and genetic disorders. Not is it beneficial for health but it also finds applications in agriculture and animal breeding. Additionally, the TALENs technology that enables gene editing with DNA binding proteins is on the verge of significant expansion. This versatile approach has uses in gene therapy, agricultural advancements and disease modelling. Both CRISPR and TALENs are ground-breaking tools with implications, for healthcare, agriculture and biotechnology.

By Application Type

The genetic engineering segment held the highest revenue share of 69.2%. This growth can be attributed to the increasing demand for stem cell therapies focus on stem cell research by industry players and significant funding from both private and public sectors. Moreover, factors such as the growing demand for biopharmaceuticals and the expanding use of drug discovery are anticipated to drive the growth of this segment.

On the other hand, there is potential for significant growth in animal genetic engineering. This can be attributed to the ranging application of editing techniques in creating new animal models and enhancing animal health and productivity. Meanwhile it is projected that the plant genetic engineering sector will achieve a CAGR in the coming years. This growth is primarily driven by our need to increase crop yields and equip plants with resilience against changes, within the sector.

By End-User Type

The biotechnology and pharmaceutical companies segment dominated the gene editing market and accounted for the major revenue share of 53.2%. The main driver of revenue growth is the increasing number of research efforts focused on discovering therapeutics. Furthermore, the market is expected to experience growth due, to the rise in developments by players in the industry.

For example, on April 27th, 2021 CANbridge Pharmaceuticals Inc., a company based in China that specializes in developing life changing therapeutics and LogicBio Therapeutics Inc., a stage genetic medicine company announced a strategic partnership and option agreement aimed at treating rare and serious diseases from childhood through adulthood. According to the terms of this agreement CANbridge has been given an option for licensing LogicBios LB 001 technology—a gene editing technology based on their GeneRideTM platform—which holds potential, for treating Methylmalonic Acidemia (MMA) in Greater China.

Key Market Segment

By Technology

• CRISPR
• TALEN
• ZFN
• Antisense
• Others

By Application

• Genetic Engineering
• Gene Therapy
• Cell Line Engineering
• Others

By End User

• Biotechnology and Pharmaceutical Companies
• Contract Research Organizations and Academic
• Government Research Institutes

Growth Opportunities

More Investment in Genetic Research Will Propel the Gene Editing Market

Governments around the world have made investments in genomics, which has resulted in advancements in genome editing technologies. This financial support is being used to conduct research in universities and government institutes leading to a surge of initiatives focused on genomics research. As a result, the genome editing market is expected to experience growth in the future. It's worth noting that in the United States over 20 federal agencies provide funding for research and development efforts conducted by companies thereby contributing to the creation of essential materials and methods.

The National Human Genome Research Institute and the National Institutes of Health (NIH) play roles in providing funding for biomedical research. In 2021, the NIH allocated USD 1.6 million specifically for researching advancements in human genome editing. The development of medications targeting disorders has also played a significant role, in reducing mortality rates and further propelling the growth of the gene editing market.

High R&D Spending and Rapid Adoption of Sophisticated Technologies Are Moving the Gene Editing Market Forward

The gene editing market on a scale is being driven by its wide range of applications in areas such as therapeutics, agriculture, biotechnology and mutation studies. Techniques like recombination show potential for enhancing crop quality. Furthermore, the markets growth can be attributed to the growing utilization of editing in treating diseases and genetic disorders. Investments from both private sectors in research and development also play a role in driving the gene editing market expansion opening up profitable prospects, for the future.

Drug Discovery Using Functional Genes

The use of advanced gene editing tools, like CRISPR Cas9, combined with genomics represents a step forward in the field of drug discovery. This collaboration allows for modifications to genes providing insights into how they function within biological processes and contribute to disease mechanisms. It simplifies the development of drugs by identifying targets along disease pathways opening up possibilities for medicine and breakthroughs in rare genetic disorders. Moreover, it expedites the process of drug screening by utilizing models, which revolutionizes the development of therapies. This integration marks an era, in research empowering scientists to unravel disease mechanisms and create treatments.

Latest Trends

Genetic Disorder Targeted Therapies

Advancements, in gene editing technologies have revolutionized the treatment of disorders. These technologies allow for targeting of genetic mutations leading to therapies that can be customized for individual patients. This approach not increases effectiveness. Also reduces unintended side effects. As a result, untreatable genetic diseases are now within reach of cures.

CRISPR-Based Treatments for Inherited Diseases

CRISPR based editing tools have emerged as a game changing solution in the field of gene editing. Their simplicity and versatility make them particularly effective in targeting inherited conditions such as sickle cell anaemia and certain types of blindness. This breakthrough holds promise for individuals with disorders offering new hope for effective treatments.

Ex Vivo Gene Editing Techniques Expansion

The expansion of ex vivo gene editing techniques has brought about advancements in stem cell therapies. Modifying cells outside the body allows for corrections to each patient opening up possibilities for curing a wide range of genetic conditions. This development has the potential to transform medicine and provide avenues for treatment.

Improved Delivery Systems

Efficient and safe delivery systems are essential, for the application of gene editing tools. The development of delivery methods is critical to ensure outcomes in various medical settings. Advancements, in delivery methods like vectors and carriers based on nanoparticles are revolutionizing gene editing by making it easier to access and less invasive. This development is a game changer as it tackles a hurdle, in unleashing the potential of gene editing treatments.

Regional Analysis

North America emerged as the leading region in the gene editing market accounting for 40% of the market share followed by Europe and Asia Pacific. The dominance of North America is expected to continue due to funding for modification support from the government increased adoption of GM crops and advancements in gene therapy.

Europe with its pharmaceutical and biotech companies expanding research institutes and substantial investments in research and development (R&D) holds potential to capture a significant market share.

At the time Asia Pacific shows promising growth prospects fueled by increased investments from players and government initiatives aimed at supporting startups. Additionally, Latin America exhibits encouraging growth opportunities in the genome editing market driven by a rise, in pharmaceutical and biotech activities.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Player Analysis

The gene editing market is highly competitive with companies vying for market share through research, development, partnerships and investments. The industry is moderately fragmented, as competition intensifies and strategic decisions are made to improve efficiency.

To expand their product portfolios and introduce offerings companies have pursued mergers and collaborations. The growth of players in the industry depends on factors such as market conditions, government support and industry advancements. Key manufacturers in the gene editing market are focused on developing products with technologies. Increased investment, in research and development is expected to drive market growth.

Key Players in Gene Editing Market

• Thermo Fisher Scientific
• Merck KGAA
• Horizon Discovery Group Plc
• Genscript
• Biotech Corporation
• Sangamo Biosciences
• Integrated DNA Technologies
• Lonza Group Ltd
• New England Biolabs
• Origene Technologies
• Transposagen
• Biopharmaceuticals
• New England Biolabs, Inc
• CRISPR Therapeutics
• Intellia Therapeutics, Inc.
• Caribou Biosciences, Inc.
• AstraZeneca
• Takara Bio USA
• Egenesis Inc.

Recent Development

• Intellia Therapeutics received clearance, from the FDA on October 2023 allowing them to commence a Phase III trial, for their therapy aimed at treating genetic liver disease, known as NTLA 2001.
• On September 2023 researchers achieved a breakthrough by modifying the composition of a CRISPR Cas13 system making it more effective, in combating viruses. This advancement brings forth possibilities, for developing approaches.
• On September 2023 scientists introduced NICER, a method, for editing genomes. This technique demonstrates a reduction in, off target mutations when compared to CRISPR/Cas9. The discovery of NICER marks a step forward in modification by providing a more accurate and refined approach.
• In January 2023 a Korean company called GenKOre joined forces with a company, from the United States to explore new possibilities in the field of, in vivo gene editing therapies.

Report Scope